AstraZeneca and Pfizer enter agreement for over-the-counter NEXIUM; AstraZeneca raises 2012 guidance

Monday, 13 August 2012

NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval

AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States, Europe and the rest of the world. Under the agreement, Pfizer will make an upfront payment of $250 million to AstraZeneca and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.

Read the full press release

Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar